In summary, specific genetic risk factors predispose patients with schizophrenia to develop OCS induced by antipsychotic treatment, and risk-conferring polymorphisms in genes linked to the glutamatergic system, such as SLC1A1, DLGAP3, and GRIN2B, have been identified [10] (Table 1). The gene discussed is DLGAP3; the disease is schizophrenia.